Company Score

Industry Pharmaceuticals
Country United Kingdom
Year Added 2018
Impact Ratings 569
Impact Notes 19
SDG Covered 8 out of 17

GSK is a global healthcare company, researching and developing products for its three main arms of business - pharmaceuticals, vaccines and consumer health care. It is a British multinational company with a head office based in London.

Its top-selling products are Advair, Avodart, Flovent, Augmentin, Lovaza and Lamictal. Well recognised consumer products include Sensodyne and Aquafresh toothpaste, Horlicks, Nicorette and Night Nurse. Its pharma business develops and sells drugs for the treatment of acute illnesses and diseases, and the vaccination arm develops vaccinations. GSK currently delivers over 2 million vaccine doses per day in 160 countries. The World Health Organization 'Model List of Essential Medicines', feature many of GSK legacy products such as amoxicillin, mercaptopurine, and pyrimethamine.

Read about GlaxoSmithKline and its impact below.

Impact notes

Good Health and Well-being

GlaxoSmithKline' popular medicine Zinetac has Ranitidine which is a Carcinogen

Profile Nadia Hussain
Icon time Mon Dec 28th, 2020 at 9:32am

In 7 years, from  2011-2017, the FDA received more than 5.4Mn reports of side effects of drugs prescribed by the doctors; this also included 1Mn death1. Indeed, prescription drugs are often accompanied by undesirable secondary effects1. Manufacturers need to disclose the potential side effects so that the prescribing doctor and patient can weigh the benefits against the risks1.

Climate Action

GlaxoSmithKline's total GHG emission (scope 1,2 & 3) in 2019 were 5.77 million tonnes

Profile Nadia Hussain
Icon time Mon Dec 21st, 2020 at 7:11pm

Globally 50 billion tonnes of CO2 equivalent of greenhouse gas (GHG) is emitted every year1. According to a study published in the Journal of Cleaner Production in 2015 pharmaceutical industry contribution to GHG emission was bigger than that of the automotive industry2.  Although the pharmaceutical sector is 28% smaller it is 13% more polluting than the automotive sector2. In order to meet the reduction targets of the Paris Agreement the pharmaceutical industry will have to reduce its emission by 58.6% by 20252.

Responsible Consumption and Production

The total waste generated by GlaxoSmithKline in 2019 was 117,000 tonnes

Profile Nadia Hussain
Icon time Fri Dec 18th, 2020 at 7:40am

Globally almost 100,000 tonnes of pharmaceutical products are manufactured every year1. According to the WHO, 85% of pharmaceutical waste is non-hazardous, and 15% is hazardous waste2. Improper disposal of unused medicines accounts for 10%, and the production process accounts for 2% of the total waste generated3.

Affordable and Clean Energy

GlaxoSmithKline consumed 3,995 GWh of energy in 2019 and only 5% was from renewable sources

Profile Nadia Hussain
Icon time Thu Dec 17th, 2020 at 9:32pm

Fossil fuel is the source of 80% of the energy produced worldwide1. The global energy consumption in 2019 was 160 million GWh1. Renewable energy withholds the production of greenhouse gases, particularly CO2, that causes global warming3. The 70% energy requirement of the industrial sector is fulfilled by non-renewable sources4.

Good Health and Well-being

GlaxoSmithKline’s high pricing makes medicines inaccessible for lupus and asthma patients

Profile Mahima Bajpai
Icon time Tue Aug 25th, 2020 at 1:08pm

The promotion of affordable and fair price intervention is essential for achieving universal health coverage1. However, companies are exploiting the patients by charging prices that are not affordable1. This is a concern for the people who have chronic diseases, including asthma and lupus9;p1. Globally, lupus affects 40-100 individuals out of every 100,000 people2, and asthma affects over 339 million people3.